步长制药持股公司石榴云医登陆纳斯达克

Group 1 - The core viewpoint of the articles highlights the strategic move of the company in digital healthcare through its stake in POMDOCTOR LIMITED, which has successfully listed on NASDAQ, marking a significant step towards integrating traditional medicine with digital health solutions [1] - The company holds approximately 15% of POMDOCTOR LIMITED's total shares post-IPO, indicating a substantial financial investment and a commitment to the digital health sector [1] - The business model of POMDOCTOR LIMITED focuses on chronic disease management, covering areas such as hypertension, diabetes, and cardiovascular diseases, which aligns with the company's existing product portfolio [1] Group 2 - The company has engaged in a "cancellation-style buyback" strategy to reduce its share capital, accumulating nearly 1.8 billion yuan in buybacks since its listing in 2016, which reflects its commitment to enhancing shareholder returns [2] - The chairman of the company actively leads various charitable initiatives, investing significant resources in poverty alleviation, education support, and medical assistance, showcasing its dedication to social responsibility [2] - The company aims to drive future growth through a dual approach of continuous R&D and social responsibility, focusing on modernizing traditional Chinese medicine and fostering high-tech innovation in the industry [2]